MX2020008559A - Compuestos heterocíclicos como inhibidores de la quinasa. - Google Patents
Compuestos heterocíclicos como inhibidores de la quinasa.Info
- Publication number
- MX2020008559A MX2020008559A MX2020008559A MX2020008559A MX2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A MX 2020008559 A MX2020008559 A MX 2020008559A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compounds
- kinase inhibitors
- compounds
- find
- cdk6
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Se proporcionan compuestos heterocíclicos como inhibidores de CDK4 o CDK6 u otros inhibidores de CDK; los compuestos pueden usarse como agentes terapéuticos para el tratamiento de enfermedades y pueden usarse particularmente en oncología.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631437P | 2018-02-15 | 2018-02-15 | |
PCT/US2019/018244 WO2019161224A1 (en) | 2018-02-15 | 2019-02-15 | Heterocyclic compounds as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008559A true MX2020008559A (es) | 2021-01-08 |
Family
ID=67542098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008559A MX2020008559A (es) | 2018-02-15 | 2019-02-15 | Compuestos heterocíclicos como inhibidores de la quinasa. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11174252B2 (es) |
EP (1) | EP3752491A4 (es) |
JP (1) | JP2021514359A (es) |
KR (1) | KR20200131246A (es) |
CN (1) | CN112334451A (es) |
AU (1) | AU2019220746A1 (es) |
BR (1) | BR112020015431A2 (es) |
CA (1) | CA3089592A1 (es) |
IL (1) | IL276509A (es) |
MA (1) | MA51846A (es) |
MX (1) | MX2020008559A (es) |
SG (1) | SG11202007754UA (es) |
WO (1) | WO2019161224A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
JP7301958B2 (ja) | 2018-05-25 | 2023-07-03 | オンコキューブ セラピューティクス エルエルシー | 新規な抗がん薬候補としての非常に強力なtacc3阻害剤 |
KR20220047329A (ko) * | 2019-08-14 | 2022-04-15 | 누베이션 바이오 인크. | 키나제 억제제로서의 헤테로시클릭 화합물 |
US20220281859A1 (en) * | 2019-08-14 | 2022-09-08 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
CN116249701A (zh) * | 2020-10-12 | 2023-06-09 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022169897A1 (en) * | 2021-02-03 | 2022-08-11 | Nuvation Bio Inc. | Crystalline forms of a cyclin-dependent kinase inhibitor |
EP4323351A1 (en) * | 2021-04-12 | 2024-02-21 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
WO2022236255A2 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
WO2022236253A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
WO2022236257A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
WO2022236256A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
CN113264920B (zh) * | 2021-05-10 | 2022-09-02 | 中国药科大学 | 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用 |
WO2022261643A1 (en) * | 2021-06-09 | 2022-12-15 | Nuvation Bio Inc. | Treating cancers with a cyclin-dependent kinase inhibitor |
WO2023205892A1 (en) * | 2022-04-27 | 2023-11-02 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cdk inhibitors and pharmaceutical uses thereof |
WO2023208172A1 (en) * | 2022-04-29 | 2023-11-02 | Beigene , Ltd. | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
WO2024022487A1 (en) * | 2022-07-29 | 2024-02-01 | Allorion Therapeutics Inc | Aminoheteroaryl kinase inhibitors |
WO2024051702A1 (zh) * | 2022-09-05 | 2024-03-14 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK12472002A3 (sk) | 2000-03-06 | 2003-04-01 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz |
EP1373257B9 (en) * | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
MX2007001126A (es) | 2004-07-27 | 2007-09-25 | Sgx Pharmaceuticals Inc | Moduladores de heterociclo cinasa de anillo fusionado. |
US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
DE602006016303D1 (de) | 2005-08-25 | 2010-09-30 | Pharmacopeia Llc | 3,4-dihydro-2H-benzoÄ1,4Üoxazin- und 3,4-dihydro-2H-benzoÄ1,4Üthiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN |
CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
DK2331547T3 (da) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
US20130231348A1 (en) | 2010-06-09 | 2013-09-05 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
WO2011156775A2 (en) | 2010-06-10 | 2011-12-15 | Afraxis, Inc. | 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
EP2580216A4 (en) | 2010-06-10 | 2014-07-23 | Afraxis Holdings Inc | 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
MY165584A (en) | 2010-07-29 | 2018-04-05 | Rigel Pharmaceuticals Inc | Ampk-activating heterocyclic compounds and methods for using the same |
ES2525866T3 (es) | 2010-08-05 | 2014-12-30 | Temple University - Of The Commonwealth System Of Higher Education | 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
WO2013175415A1 (en) | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
US10016439B2 (en) | 2014-01-31 | 2018-07-10 | Ono Pharmaceutical Co., Ltd. | Fused imidazole compounds |
CA2950330C (en) | 2014-05-28 | 2019-04-30 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
WO2016015598A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
WO2016015605A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
JP6726677B2 (ja) | 2015-03-11 | 2020-07-22 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | 抗がん剤としての置換2−h−ピラゾール誘導体 |
CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
WO2017101763A1 (en) | 2015-12-13 | 2017-06-22 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
WO2017114351A1 (en) | 2015-12-27 | 2017-07-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
TWI736578B (zh) | 2016-02-06 | 2021-08-21 | 大陸商上海複尚慧創醫藥研究有限公司 | 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 |
CN107286180B (zh) | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
CN107286134B (zh) | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2,4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
SI3442947T1 (sl) | 2016-04-15 | 2023-10-30 | Epizyme, Inc. | Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2 |
CA3018434A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
US10835535B2 (en) | 2016-05-07 | 2020-11-17 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
EP3478294A4 (en) | 2016-07-01 | 2020-06-10 | G1 Therapeutics, Inc. | PYRIMIDINE-BASED ANTIPROLIFERATIVE ACTIVE SUBSTANCES |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
NZ749275A (en) | 2016-07-01 | 2023-06-30 | G1 Therapeutics Inc | Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines |
WO2018086591A1 (zh) | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
TWI732083B (zh) | 2016-12-22 | 2021-07-01 | 大陸商貝達藥業股份有限公司 | 苯并咪唑衍生物、其藥物組合物及其應用 |
CN107382974B (zh) | 2017-06-08 | 2020-06-05 | 扬州市三药制药有限公司 | 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
JP7337395B2 (ja) | 2018-01-29 | 2023-09-04 | ベータ ファーマ,インコーポレイテッド | Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用 |
WO2019165204A1 (en) | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
WO2020006210A1 (en) | 2018-06-27 | 2020-01-02 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
WO2020023480A1 (en) | 2018-07-23 | 2020-01-30 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
AU2019310595B2 (en) | 2018-07-27 | 2022-11-24 | 1200 Pharma Llc | CDK inhibitors and uses thereof |
CN110835334B (zh) | 2018-08-16 | 2022-10-18 | 中国药科大学 | 吲哚取代唑类化合物及其用途 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US20220041577A1 (en) | 2018-11-30 | 2022-02-10 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor |
CN113166110B (zh) | 2018-12-12 | 2023-08-11 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
-
2019
- 2019-02-15 MX MX2020008559A patent/MX2020008559A/es unknown
- 2019-02-15 US US16/277,355 patent/US11174252B2/en active Active
- 2019-02-15 SG SG11202007754UA patent/SG11202007754UA/en unknown
- 2019-02-15 EP EP19754726.8A patent/EP3752491A4/en not_active Withdrawn
- 2019-02-15 BR BR112020015431-8A patent/BR112020015431A2/pt not_active Application Discontinuation
- 2019-02-15 CA CA3089592A patent/CA3089592A1/en active Pending
- 2019-02-15 WO PCT/US2019/018244 patent/WO2019161224A1/en unknown
- 2019-02-15 MA MA051846A patent/MA51846A/fr unknown
- 2019-02-15 AU AU2019220746A patent/AU2019220746A1/en not_active Abandoned
- 2019-02-15 JP JP2020543494A patent/JP2021514359A/ja active Pending
- 2019-02-15 KR KR1020207026424A patent/KR20200131246A/ko not_active Application Discontinuation
- 2019-02-15 CN CN201980025159.XA patent/CN112334451A/zh active Pending
-
2020
- 2020-08-05 IL IL276509A patent/IL276509A/en unknown
-
2021
- 2021-10-01 US US17/449,779 patent/US20230062022A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11174252B2 (en) | 2021-11-16 |
BR112020015431A2 (pt) | 2020-12-08 |
US20230062022A1 (en) | 2023-03-02 |
CA3089592A1 (en) | 2019-08-22 |
CN112334451A (zh) | 2021-02-05 |
EP3752491A4 (en) | 2021-12-01 |
KR20200131246A (ko) | 2020-11-23 |
IL276509A (en) | 2020-09-30 |
MA51846A (fr) | 2021-04-21 |
US20190248774A1 (en) | 2019-08-15 |
AU2019220746A1 (en) | 2020-08-27 |
WO2019161224A1 (en) | 2019-08-22 |
EP3752491A1 (en) | 2020-12-23 |
JP2021514359A (ja) | 2021-06-10 |
SG11202007754UA (en) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
BR112022002532A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
IL275948A (en) | History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses | |
EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
JOP20200209A1 (ar) | مثبطات cd73 | |
EP4010080C0 (en) | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
MX2022004390A (es) | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). | |
CR20220066A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
EA201790122A1 (ru) | Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение | |
PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
MX2017004128A (es) | Derivados de diarilurea como inhibidores de quinasa p38. | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
EP3877422A4 (en) | THERAPEUTIC DOSING SCHEDULES FOR THE TREATMENT OF CANCER WITH ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS |